Elypta ^Companies

Elypta is an organization that is focused on preventing cancer mortality through early detection. They are developing a metabolism-based liquid biopsy platform that uses a new IVD laboratory assay kit and artificial intelligence algorithms. Elypta is currently sponsoring the clinical trial series AURORAX to investigate applications in renal cell carcinoma and is exploring other indications as well. They measure the GAGome, which are system biomarkers of tumor metabolism, and use machine learning to detect cancer signatures noninvasively. Elypta is open to partnerships with academia and industry for the development of companion diagnostics, and they are also interested in collaborating with top talents in their development team.